Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Mantle Cell Lymphoma
94%
Wisconsin
94%
Medical Colleges
94%
Clinical Trials Network
94%
Clinical Centers
94%
Factor VIII (FVIII)
94%
Marrow Transplant
94%
Cell Therapy
55%
High Risk
54%
Hematopoietic Stem Cell Transplant
34%
Relapsed/refractory Mantle Cell Lymphoma
27%
Progression-free Survival
27%
T Cells
27%
Improved Outcomes
27%
Multi-target
27%
State of Science
27%
Hemophilia
21%
Platelets
21%
Transplantation Therapy
20%
Gene Therapy
20%
Core-center
20%
Accruals
20%
Phase I Study
20%
First-in-human
20%
Therapeutic Program
20%
Vascular Injury
14%
CD19
13%
Efficacy Data
13%
Single Center
13%
Lymphoma
13%
Cytokine Release Syndrome
13%
Poor Survival
13%
TP53 mutation
13%
High-quality Data
13%
Adoptive Cell Therapy
13%
Unmet Medical Need
13%
B-cell Malignancies
13%
B-cell Antigens
13%
CD20
13%
Data Submission
13%
Overall Response Rate
13%
Multicenter Cohort Study
13%
17p Deletion
13%
Maximum Tolerated Dose
13%
Complex Karyotype
13%
Cell-based
13%
Adverse Features
13%
Optimal Organization
13%
Safety Data
13%
Poor Outcome
13%
Cellular Products
13%
Histology
13%
Symposium Report
13%
Treatment Strategy
13%
Newly Diagnosed
13%
Chimeric Antigen Receptor T Cells (CAR-T)
13%
CD19 Expression
13%
Lymphoma Patients
13%
Overall Survival
13%
Toxicity Profile
13%
Blastoids
13%
CD20 Expression
13%
Dose-escalation Study
13%
B-cell non-Hodgkin Lymphoma (B-NHL)
13%
Chimeric Antigen Receptor Cells
13%
Platelet Granules
7%
EnGraft
7%
Unmet Needs
7%
Phase Trials
7%
Clot Formation
7%
Gene Therapy for Hemophilia
7%
High-titer Inhibitor
7%
Limiting Availability
7%
Bypassing Agents
7%
Cell Selection
7%
Platelet Receptors
7%
Xenograft Mouse Model
7%
Reduced-intensity Conditioning
7%
Mutagenesis
7%
Titer
7%
Gene-modified
7%
Non-associated
7%
Primary Cells
7%
Preclinical Testing
7%
Apheresis Product
7%
Immunogenicity
7%
Cell-to-cell
7%
Immune-privileged Sites
7%
CD34+ Cells
7%
Center-based
7%
Hemostasis
7%
Scientific Idea
7%
Severe Haemophilia A
7%
Platelet Activation
7%
FVIII Inhibitors
7%
Lentiviral Vector
7%
Syngeneic Mouse Model
7%
Platelet Aggregation
7%
Megakaryocytes
7%
Clinical Trial Design
7%
Von Willebrand Disease
7%
B Domain
7%
Major Innovation
7%
Engraftment
7%
Medicine and Dentistry
Cell Therapy
100%
Mantle Cell Lymphoma
94%
Haemophilia A
94%
Clinical Trial
94%
Platelet
94%
Gene Therapy
57%
Blood Vessel Injury
47%
Hematopoietic Cell
44%
T Cell
31%
B Cell
31%
Immunogenicity
23%
Von Willebrand Disease
23%
Thrombocyte Receptor
23%
Engraftment
23%
Blood Clotting
23%
Promoter Region
23%
Infusion
23%
Thrombocyte Aggregation
23%
Apheresis
23%
Thrombocyte Activation
23%
Clinical Trial Design
23%
Mutagenesis
23%
Reduced Intensity Conditioning
23%
Megakaryocyte
23%
Cell Line
23%
Blood Stasis
23%
Lentivirus Vector
23%
Xenograft
23%
Progression Free Survival
21%
CD19 Antigen
10%
Median Follow Up
10%
CD20 Antigen
10%
Cell Antigen
10%
Cancer
10%
Cytokine Release Syndrome
10%
Karyotype
10%
Diseases
10%
CD20
10%
Histology
10%
Non-Hodgkin Lymphoma
10%
Overall Survival
10%
Chimeric Antigen Receptor
10%
Immunology and Microbiology
Lymphoma Cell
94%
Platelet
94%
Hematopoietic Cell
39%
Lineages
37%
Titer
37%
B Cell
31%
T Cell
31%
Progression Free Survival
21%
Mouse Model
18%
Syngenic
18%
Cell Line
18%
Immunogenicity
18%
Thrombocyte Aggregation
18%
Thrombocyte Activation
18%
CD34 Selection
18%
Promoter Region
18%
Xenograft
18%
Engraftment
18%
Mutagenesis
18%
Megakaryocyte
18%
Lentivirus Vector
18%
Hemostasis
18%
Apheresis
18%
Blood Clotting
18%
Cell Antigen
10%
CD19
10%
CD19 Antigen
10%
CD20 Antigen
10%
Karyotype
10%
Cytokine Release Syndrome
10%
Chimeric Antigen Receptor
10%
CD20
10%
Overall Survival
10%